Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2002 1
2003 1
2007 2
2008 3
2009 1
2011 1
2012 4
2013 4
2014 11
2015 4
2016 3
2017 6
2018 7
2019 5
2020 14
2021 22
2022 16
2023 1
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 35896462

98 results
Results by year
Filters applied: . Clear all
Page 1
A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial.
Rodríguez-Rubio M, Figueira JC, Acuña-Castroviejo D, Borobia AM, Escames G, de la Oliva P. Rodríguez-Rubio M, et al. Trials. 2020 Aug 5;21(1):699. doi: 10.1186/s13063-020-04632-4. Trials. 2020. PMID: 32758298 Free PMC article. Clinical Trial.
Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment.
McCleery J, Abraham RP, Denton DA, Rutjes AW, Chong LY, Al-Assaf AS, Griffith DJ, Rafeeq S, Yaman H, Malik MA, Di Nisio M, Martínez G, Vernooij RW, Tabet N. McCleery J, et al. Cochrane Database Syst Rev. 2018 Nov 1;11(11):CD011905. doi: 10.1002/14651858.CD011905.pub2. Cochrane Database Syst Rev. 2018. PMID: 30383288 Free PMC article.
A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial.
García IG, Rodriguez-Rubio M, Mariblanca AR, de Soto LM, García LD, Villatoro JM, Parada JQ, Meseguer ES, Rosales MJ, González J, Arribas JR, Carcas AJ, de la Oliva P, Borobia AM. García IG, et al. Trials. 2020 Jun 3;21(1):466. doi: 10.1186/s13063-020-04436-6. Trials. 2020. PMID: 32493475 Free PMC article.
Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
Stroehlein JK, Wallqvist J, Iannizzi C, Mikolajewska A, Metzendorf MI, Benstoem C, Meybohm P, Becker M, Skoetz N, Stegemann M, Piechotta V. Stroehlein JK, et al. Cochrane Database Syst Rev. 2021 May 24;5(5):CD015043. doi: 10.1002/14651858.CD015043. Cochrane Database Syst Rev. 2021. PMID: 34029377 Free PMC article.
Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Crippa JAS, Pacheco JC, Zuardi AW, Guimarães FS, Campos AC, Osório FL, Loureiro SR, Dos Santos RG, Souza JDS, Ushirohira JM, Ferreira RR, Mancini Costa KC, Scomparin DS, Scarante FF, Pires-Dos-Santos I, Mechoulam R, Kapczinski F, Fonseca BAL, Esposito DLA, Passos ADC, Dal Fabbro AL, Bellissimo-Rodrigues F, Arruda E, Scarpelini S, Andraus MH, Nather Junior JC, Wada DT, Koenigkam-Santos M, Santos AC, Busatto Filho G, Hallak JEC. Crippa JAS, et al. Cannabis Cannabinoid Res. 2022 Oct;7(5):658-669. doi: 10.1089/can.2021.0093. Epub 2021 Oct 7. Cannabis Cannabinoid Res. 2022. PMID: 34619044 Clinical Trial.
98 results